RxDoctor Payments Data

Nicolas Hernandez, DO

Family Medicine · la Habra, CANPI 1992941751

Payments from drug & device makers

$1,190in general payments, 2019–2025

Across 63 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$276
  • Eisai Inc.$196
  • AbbVie$78
  • Novo Nordisk$74
  • Bristol Myers Squibb$69
  • AstraZeneca$67
  • plus $430 from 13 others

What the payments were for

  • Consulting fees$121%
  • Food & beverage$1,17899%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,190 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$34,085
Medicare patients
117
Services billed
366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$167,616
JardianceEmpagliflozin86$127,864
RybelsusSemaglutide74$101,030
FarxigaDapagliflozin Propanediol66$82,122
TrulicityDulaglutide48$61,817
JanuviaSitagliptin Phosphate56$56,930
EliquisApixaban42$50,959
MounjaroTirzepatide26$27,438
TradjentaLinagliptin13$18,318
Breo ElliptaFluticasone/Vilanterol21$16,688
JanumetSitagliptin Phos/Metformin Hcl12$16,599
XareltoRivaroxaban13$13,496
Metformin Hcl341$8,355
Atorvastatin Calcium639$7,665
BelsomraSuvorexant17$6,913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$74$268,646183 claims
Boehringer IngelheimJardiance, Tradjenta$13$146,18299 claims
AstraZenecaFarxiga$67$82,12266 claims
MerckJanuvia, Janumet, Belsomra$26$80,44285 claims
PfizerEliquis$34$50,95942 claims
GSKBreo Ellipta, Arnuity Ellipta$55$19,03132 claims
Johnson & JohnsonXarelto$35$13,49613 claims
AbbVieSynthroid$78$2,06330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in la Habra

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →